CD274 and neoplasm of esophagus: However, partly due to specimen constraints and regional disparities in incidence (i.e., its higher prevalence in developing countries, particularly East Asia) (2), few studies have focused on innate immunity in EC, and ongoing immunotherapy of patients with esophageal tumors is almost entirely restricted to targeting of the PD1/PD-L1 pathway (68).